Key takeaways
- Aromatase is the only route to estrogen, and the reaction is one-way — estradiol cannot be converted back.
- Output depends on substrate, so estradiol rising alongside testosterone is what testosterone does, not a side effect.
- Most of the enzyme sits in adipose tissue, making body composition the main determinant of estradiol.
- In men this forms a loop: more fat, more conversion, more LH suppression, less testosterone — and weight loss reverses it.
- Bone and brain make estradiol locally, so a serum value in range does not guarantee tissue supply.
Aromatase is the only enzyme in the human body that makes estrogen. Every molecule of estradiol in a man, and in a postmenopausal woman, was testosterone or androstenedione until this enzyme acted on it. That one fact explains a set of clinical patterns that otherwise look unrelated: why obesity lowers testosterone in men, why postmenopausal body fat matters for breast cancer risk, and why blocking the enzyme to feel leaner is a reliable way to damage a hormone protocol.
What the enzyme does
Aromatase — gene name CYP19A1 — is a cytochrome P450 enzyme that converts androgens to estrogens: testosterone to estradiol, androstenedione to estrone. The reaction removes a carbon from the steroid backbone and aromatises the A-ring, which is a one-way chemical change (Simpson et al., Endocr Rev 1994).
Two consequences follow, both clinical. There is no reverse reaction — estradiol cannot be converted back to testosterone, so an aromatase problem cannot be corrected downstream. And output depends on substrate: raise testosterone and, all else equal, estradiol rises with it. That is not a side effect of testosterone therapy in any meaningful sense. It is what testosterone does.
Where it is expressed, and why the location matters
- Adipose tissue — the dominant peripheral site, and the one that scales with body composition
- Brain — hypothalamus, hippocampus, amygdala and elsewhere
- Bone — osteoblasts make their own estradiol locally
- Gonads — ovarian granulosa cells premenopausally, and to a small extent the testes
- Placenta, in pregnancy, at very high activity
- Skin, vascular tissue and others, at lower levels
Much of aromatase activity is local rather than endocrine. Bone makes estradiol for bone; brain makes estradiol for brain. A serum measurement tells you what spills into circulation, not what a tissue produces for its own use — which is why a number in range does not guarantee every tissue is supplied, and why systemic inhibition has effects in places nobody was aiming at.
What turns it up
- Adipose mass. More fat tissue means more enzyme, more or less proportionally. This is the largest modifiable input.
- Inflammatory cytokines. IL-6 and TNF-α upregulate expression in adipose tissue, which is why the effect of visceral fat is larger than its mass alone predicts.
- Insulin modulates expression, so insulin resistance and aromatase activity travel together.
- Cortisol can upregulate the enzyme, linking chronic stress to the same output.
- Age. Peripheral activity tends to rise across the lifespan even at stable body composition.
- Substrate. More testosterone available means more conversion.
The first four cluster in the same person. Someone with high visceral fat, raised inflammatory markers and poor insulin sensitivity has all four levers pushed the same way at once, which is why his estradiol is often high out of proportion to his testosterone.
In men: the obesity-hypogonadism loop
Most circulating estradiol in men comes from peripheral aromatisation rather than testicular production. That makes body composition the main determinant of a man's estradiol, and it sets up a self-reinforcing loop:
- Higher adipose mass increases aromatase capacity, so a larger share of testosterone becomes estradiol and the E2-to-T ratio rises.
- Estradiol is a potent negative-feedback signal at the hypothalamus and pituitary — in men it suppresses LH secretion at least as effectively as testosterone does (Santen, on aromatisation and LH suppression in men).
- Suppressed LH means less testicular testosterone production.
- Lower testosterone makes it harder to maintain lean mass and easier to gain fat.
- More fat means more aromatase. Back to step one.
This is the mechanism behind one of the most reliable findings in male endocrinology: weight loss raises testosterone in men with obesity. Nothing is being added. Aromatase capacity is being removed, negative feedback lifts, LH recovers, and the testes resume. It is also why visceral fat in midlife men is a hormonal problem rather than a cosmetic one, and why resistance training belongs in every low-testosterone conversation — a three-day full-body programme addresses the fat mass driving the loop.
In women: the source changes at menopause
Premenopausally, ovarian granulosa cells aromatise theca-derived androgens and the ovary is the dominant source. After menopause that contribution largely ceases and peripheral aromatase — mostly adipose — becomes the main source.
Two things follow. The dominant postmenopausal estrogen becomes estrone rather than estradiol, because adipose tissue preferentially aromatises androstenedione — and estrone is the weaker of the two, so postmenopausal exposure is qualitatively different rather than simply lower. And adipose mass becomes the main determinant of that exposure, which is the mechanistic basis for the association between postmenopausal obesity and hormone-sensitive breast and endometrial cancer risk.
It is also why aromatase inhibitors are a mainstay in postmenopausal hormone-receptor-positive breast cancer: removing peripheral aromatisation removes essentially the entire estrogen supply. That completeness is the point of the drug and the source of its side effect profile — joint pain, bone loss, severe genitourinary symptoms, all predictable from the biology.
The inhibitors, and where they belong
- Anastrozole — non-steroidal, competitive, reversible
- Letrozole — non-steroidal, more potent
- Exemestane — steroidal, binds irreversibly; activity returns only as new enzyme is synthesised
The primary indication is postmenopausal hormone-receptor-positive breast cancer, where near-complete suppression is the therapeutic goal. Secondary uses include ovulation induction, some paediatric endocrinology, and selected cases of genuine estradiol excess on testosterone therapy.
That last use is where the problem is. An aromatase inhibitor prescribed to a man to reduce bloating or nipple sensitivity does not lower estradiol a little — it lowers it steeply, and the therapeutic window in men is narrow. Men driven too low report joint pain, low libido despite good testosterone, low mood, poor sleep and, over longer periods, bone loss. It is a common and avoidable outcome, and it is regularly misread as needing a higher testosterone dose. When anastrozole is and is not appropriate and low estrogen symptoms in men both cover the failure mode; the first move for most men is a dosing change, not a drug.
What the enzyme's absence proves
Congenital aromatase deficiency is rare and instructive, because it shows what estradiol was doing all along. Affected men have normal or high testosterone and no estradiol, and present with severe osteoporosis, epiphyses that never fuse so linear growth continues into adulthood, insulin resistance, abnormal lipids and impaired reproduction. Estrogen replacement corrects the bone phenotype (Bilezikian et al., N Engl J Med 1998).
Controlled experiments agree. Suppressing the axis in healthy men and adding testosterone back with or without an aromatase inhibitor separates the two hormones, and bone and body-composition outcomes track estradiol (Finkelstein et al., N Engl J Med 2013). Longitudinal data confirm that fat mass drives estradiol in men over time (Wu et al., PLoS One 2018). Congenital deficiency is the extreme version of what pharmacological inhibition does in a milder form — see testosterone and bone density for what that costs the skeleton.
The clinical pearl: aromatase is not a problem to be eliminated. It is the only route to a hormone that men need for bone, brain, vascular function and libido. Pharmacological inhibition is appropriate in specific contexts and overprescribed everywhere else. The correct first response to high estradiol on testosterone therapy is usually to change the dose, the injection frequency or the body composition driving it — estradiol management covers that order of operations.
Bottom line
Aromatase converts androgens to estrogens, irreversibly, and it is the only enzyme that does. Its activity is concentrated in adipose tissue, which makes body composition the main determinant of estradiol in men and in postmenopausal women, and which explains the obesity-hypogonadism loop, the estrogen rise after weight gain, and the reason weight loss raises testosterone. The enzyme is essential for bone, brain and vascular health, and congenital deficiency shows exactly what its absence costs. Inhibitors have a genuine and important place; used casually on testosterone therapy they remove a required hormone and create a worse problem than the one being treated. Any decision about them is a physician's after evaluation and a sensitive estradiol measurement.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
